Sugi Predict

Sugi Predict / Compounds / SCHEMBL3430000

SCHEMBL3430000

SCHEMBL3430000

O=C(O)N1CC[C@H](CO)C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TACR3 P29371 1/20 0.40
▸ ALOX5 P09917 1/20 0.39
▸ EPHX2 P34913 3/20 0.37
▸ PDK2 Q15119 1/20 0.36
▸ VNN1 O95497 1/20 0.36
▸ ITGB3 P05106 2/20 0.36
▸ ITGA2B P08514 2/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ ARG1 P05089 1/20 0.35
▸ ARG2 P78540 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ LIPE Q05469 1/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ DPP8 Q6V1X1 1/20 0.34
▸ DPP7 Q9UHL4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2772712 1.00 TACR3 (0.40) TACR3ALOX5EPHX2PDK2VNN1
SCHEMBL1698890 1.00 TACR3 (0.40) TACR3ALOX5EPHX2PDK2VNN1
SCHEMBL1183595 0.88 EPHX2 (0.48) EPHX2NPC1RAB9ASMN1; SMN2POLB
SCHEMBL3329964 0.88 EPHX2 (0.48) EPHX2NPC1RAB9ASMN1; SMN2POLB
SCHEMBL1777738 0.88 EPHX2 (0.48) EPHX2NPC1RAB9ASMN1; SMN2POLB
SCHEMBL485135 0.86 ALOX5 (0.45) TACR3ALOX5EPHX2ITGB3ITGA2B
SCHEMBL28132227 0.84 LIPE (0.41) TACR3ALOX5EPHX2PDK2VNN1
SCHEMBL27989426 0.84 LIPE (0.41) TACR3ALOX5EPHX2PDK2VNN1
SCHEMBL28132225 0.84 LIPE (0.41) TACR3ALOX5EPHX2PDK2VNN1
SCHEMBL2337182 0.83 AKR1C3 (0.46) TACR3ITGB3ITGA2BDPP8DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037328-B2 Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 PRAMANA PHARMACEUTICALS INC. (CA) 2024-07-16 — — US disclosed
US-20240199655-A1 Immunoproteasome Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-06-20 — — US disclosed
WO-2024112692-A1 CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE B (CBL-B) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-05-30 — — WO disclosed
CN-111491938-B Immunoproteasome inhibitors 普林斯匹亚生物制药公司 2024-05-24 — — CN disclosed
US-11981683-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-05-14 — — US disclosed
EP-3668877-B1 INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2024-05-01 — — EP disclosed
CN-112292129-B Novel compounds and pharmaceutical compositions thereof for the treatment of diseases 加拉帕戈斯股份有限公司 2024-04-19 — — CN disclosed
CN-117813309-A Compounds as immunomodulators for PD-L1 interactions 歌礼生物科技（杭州）有限公司 2024-04-02 — — CN disclosed
US-11925651-B2 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-03-12 — — US disclosed
CN-117580824-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-02-20 — — CN disclosed
EP-2133340-A1 Novel benzazepine derivatives Glaxo Group Limited (GB) 2009-12-16 — — EP disclosed
EP-2077266-A1 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-07-08 — — EP disclosed
US-7504432-B2 Ester derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-03-17 — — US disclosed
US-20080090799-A1 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT MSD K.K. (JP) 2008-04-17 — — US disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 — — EP disclosed
US-20070129397-A1 Ester derivatives MSD K.K. (JP) 2007-06-07 — — US disclosed
US-7192969-B2 Ester derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-03-20 — — US disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 — — US disclosed
US-20050065211-A1 Ester derivatives MSD K.K. (JP) 2005-03-24 — — US disclosed
EP-1302458-A1 ESTER DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-04-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129397-A1 Ester derivatives CHRM3, CHRM2, CHRM1 TACR3 308/4885ALOX5 1764/4885EPHX2 1014/4885
US-20240199655-A1 Immunoproteasome Inhibitors PSMC2, PSMB7, PSMB2 TACR3 4777/4885ALOX5 3785/4885EPHX2 2767/4885
US-11925651-B2 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TACR3 2629/4885ALOX5 1759/4885EPHX2 988/4885
US-20080090799-A1 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT GCKR, GCK, GPR119 TACR3 4064/4885ALOX5 3890/4885EPHX2 4280/4885
US-20050065211-A1 Ester derivatives CHRM3, CHRM2, CHRM1 TACR3 324/4885ALOX5 1757/4885EPHX2 1015/4885
US-11981683-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, MDM2 TACR3 3545/4885ALOX5 4674/4885EPHX2 3521/4885
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 TACR3 4292/4885ALOX5 1339/4885EPHX2 3994/4885
US-12037328-B2 Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 GPR119, GPR3, GPR39 TACR3 498/4885ALOX5 766/4885EPHX2 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.